Abstract
Embryonic stem cells (ESC) can potentially be manipulated in vitro to differentiate into cells and tissues of all three germ layers. This pluripotent feature is being exploited to use ESC-derived tissues as therapies for degenerative diseases and replacement of damaged organs. Although their potential is great, the promise of ESC-derived therapies will be unfulfilled unless several challenges are overcome. For example, inefficient production of ESC-derived tissues before transplantation, inability of ESC-derived tissues to integrate well into the adult microenvironments due to developmental stage incompatibility, or active immune rejection of the ESC-derived graft are all potential challenges to successful ESCderived therapies. One way to induce immunological tolerance to allogeneic tissues is via the establishment of mixed hematopoietic chimerism in which the host and donor cells are educated to recognize each other as “self”. Proof of principle that in vitro cultured ESC-derived hematopoietic progenitors can be transplanted and induce immunological tolerance to allogeneic tissues exists in mouse models. In this review, we discuss the challenges to in vitro development of a bona fide ESC-derived hematopoietic stem cell and their differentiation fate in vivo, and provide suggestions to predict the immunogenicity of specific ESC-derived hematopoietic populations before transplantation that could be used to prevent their rejection after transplantation into an adult host.
Keywords: immunological tolerance, ESC-derived graft, immune rejection of, ESC-derived therapies will, ESC-derived tissues as, development, immunology, hematopoiesis, hematopoietic progenitor, hematopoietic stem cell, tolerance, immunogenicity, Embryonic stem cells
Current Topics in Medicinal Chemistry
Title: Embryonic Stem Cell-Derived Hematopoietic Stem Cells: Challenges in Development, Differentiation, and Immunogenicity
Volume: 11 Issue: 13
Author(s): J. O. Manilay and H. L. Thompson
Affiliation:
Keywords: immunological tolerance, ESC-derived graft, immune rejection of, ESC-derived therapies will, ESC-derived tissues as, development, immunology, hematopoiesis, hematopoietic progenitor, hematopoietic stem cell, tolerance, immunogenicity, Embryonic stem cells
Abstract: Embryonic stem cells (ESC) can potentially be manipulated in vitro to differentiate into cells and tissues of all three germ layers. This pluripotent feature is being exploited to use ESC-derived tissues as therapies for degenerative diseases and replacement of damaged organs. Although their potential is great, the promise of ESC-derived therapies will be unfulfilled unless several challenges are overcome. For example, inefficient production of ESC-derived tissues before transplantation, inability of ESC-derived tissues to integrate well into the adult microenvironments due to developmental stage incompatibility, or active immune rejection of the ESC-derived graft are all potential challenges to successful ESCderived therapies. One way to induce immunological tolerance to allogeneic tissues is via the establishment of mixed hematopoietic chimerism in which the host and donor cells are educated to recognize each other as “self”. Proof of principle that in vitro cultured ESC-derived hematopoietic progenitors can be transplanted and induce immunological tolerance to allogeneic tissues exists in mouse models. In this review, we discuss the challenges to in vitro development of a bona fide ESC-derived hematopoietic stem cell and their differentiation fate in vivo, and provide suggestions to predict the immunogenicity of specific ESC-derived hematopoietic populations before transplantation that could be used to prevent their rejection after transplantation into an adult host.
Export Options
About this article
Cite this article as:
O. Manilay J. and L. Thompson H., Embryonic Stem Cell-Derived Hematopoietic Stem Cells: Challenges in Development, Differentiation, and Immunogenicity, Current Topics in Medicinal Chemistry 2011; 11 (13) . https://dx.doi.org/10.2174/156802611796117702
DOI https://dx.doi.org/10.2174/156802611796117702 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Extrahepatic Metabolism may Complicate the IVIVC in Rats
Drug Metabolism Letters Bone Marrow Aspiration/Biopsy in the Evaluation of Fever of Unknown Origin in Patients with AIDS
Infectious Disorders - Drug Targets Targeting Trail Towards the Clinic
Current Drug Targets The Nuclear Orphan Receptor NR4A1 and NR4A3 as Tumor Suppressors in Hematologic Neoplasms
Current Drug Targets Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients
Recent Patents on Anti-Cancer Drug Discovery Ricin and Saporin: Plant Enzymes for the Research and the Clinics
Current Chemical Biology Advances in Lentiviral Vectors: A Patent Review
Recent Patents on DNA & Gene Sequences Plasma-Free Amino Acid Profiling of Nasal Polyposis Patients
Combinatorial Chemistry & High Throughput Screening Molecular Mechanisms of Epigenetic Regulators as Activatable Targets in Cancer Theranostics
Current Medicinal Chemistry Developing Target Therapy Against Oncogenic Tyrosine Kinase in Myeloid Maliganacies
Current Pharmaceutical Biotechnology Anti-Tumor Monoclonal Antibodies in Conjunction with β-Glucans: A Novel Anti- Cancer Immunotherapy
Current Medicinal Chemistry Recent Advances in the Development of Selective Mcl-1 Inhibitors for the Treatment of Cancer (2017-Present)
Recent Patents on Anti-Cancer Drug Discovery Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Regulatory T Cells in Cancer Biology: A Possible New Target for Biochemical Therapies
Mini-Reviews in Medicinal Chemistry Pulmonary Manifestations of Rheumatoid Arthritis, Psoriatic Arthritis and Peripheral Spondyloarthritis: Prevalence, Diagnostic Approach and Treatment Options
Current Rheumatology Reviews Recent Development in Nano-Sized Dosage Forms of Plant Alkaloid Camptothecin-Derived Drugs
Recent Patents on Anti-Cancer Drug Discovery Biological Agents in Rheumatoid Arthritis: A Cross-Link Between Immune Tolerance and Immune Surveillance
Current Rheumatology Reviews Older and New Formulations of Cladribine. Pharmacology and Clinical Efficacy in Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery Obesity and Inflammation: Colorectal Cancer Engines
Current Molecular Pharmacology Toll-Like Receptors and their Role in Hematologic Malignancies
Current Molecular Medicine